# A Study Evaluating Cadonilimab Injection in Combination With Regorafenib for the Advanced Hepatocellular Carcinoma

> **NCT05644379** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Tianjin Medical University Cancer Institute and Hospital** · enrollment: 30 (estimated)

## Conditions studied

- Advanced Hepatocellular Carcinoma That Has Failed at Least One Prior Systemic Therapy

## Interventions

- **DRUG:** Cadonilimab Injection
- **DRUG:** Regorafenib

## Key facts

- **NCT ID:** NCT05644379
- **Lead sponsor:** Tianjin Medical University Cancer Institute and Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-11-24
- **Primary completion:** 2025-11-01
- **Final completion:** 2026-11
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-02-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05644379

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05644379, "A Study Evaluating Cadonilimab Injection in Combination With Regorafenib for the Advanced Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05644379. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*